サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アルツハイマー病治療薬の世界市場- 2023-2030
市場調査レポート
商品コード
1290432

アルツハイマー病治療薬の世界市場- 2023-2030

Global Alzheimer Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アルツハイマー病治療薬の世界市場- 2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

アルツハイマー病治療薬の世界市場は、2022年に39億7,000万米ドルに達し、2030年には最大77億米ドルに達することで有利な成長を遂げると予測されています。世界のアルツハイマー病治療薬市場は、予測期間2023年から2030年の間に8.7%のCAGRを示すと予想されています。

アルツハイマー型認知症治療薬の世界市場は、認知症を含む慢性疾患の有病率の増加、治療パイプラインの規模の拡大、診断や医薬品開発のためのバイオマーカーの支出、早期発見のためのより高度な診断薬の創出などの要因によって拡大しています。

アルツハイマー病治療薬市場の薬剤タイプの範囲は、ドネペジル、ガランタミン、リバスチグミン、メマンチンなどのアルツハイマー病治療薬からなり、アルツハイマー病治療薬タイプの市場シェアを高めています。これらの薬は、いくつかの行動や認知の問題を軽減または調整することができます。また、新興諸国におけるアルツハイマー型認知症治療薬の開発および今後の承認は、市場成長への明るい展望を生み出しています。

市場力学

医薬品開発におけるバイオマーカーの使用と大規模なパイプラインがアルツハイマー病治療薬市場の成長を促進します

薬の開発には高いリスクが伴うが、バイオマーカーはそのリスクを軽減し、技術的な成功を高める実用的な手段です。アルツハイマー病の解明は急速に進んでおり、重要な生物学的事象が特定されつつあります。このような事象には、脳画像や血液中、脳脊髄液中などに見られるバイオマーカーが付随することがあります。

これらのバイオマーカーを医薬品開発プロセスの改善に活用することで、アルツハイマー型認知症治療薬の創製に伴うリスクを低減できる可能性があります。その結果、アルツハイマー型認知症治療薬の市場開拓は、AD治療薬開発におけるバイオマーカーの重要性の高まりによって推進されています。

研究開発の進展とアルツハイマー病の有病率の上昇が、メーカーに有利な機会を創出します

主要企業が最先端の技術改良のために研究開発能力に多額の投資を行っているため、市場には発展的な機会が存在します。市場に影響を与えるもう一つの動向は、アルツハイマー病の治療に対する需要の高まりです。World Alzheimer Reportによると、現在、アルツハイマー病やそれに関連する認知症の患者数は5,000万人であり、2050年にはその数が1億5,200万人に増加すると予想されています。

さらに、FDAは、記憶喪失、見当識障害、思考や推論の問題などアルツハイマー病の認知的副作用を治療するために、コリンエステラーゼ阻害剤（Aricept、Exelon、Razadyne）およびメマンチン（Namenda）という2種類の薬理クラスの使用を許可しています。アルツハイマー病の診断と治療のために、より多くの臨床試験が実施されるようになり、その結果、市場は上昇すると思われます。

後発医薬品の高い失敗率が市場成長の妨げになる

しかし、アルツハイマー病治療薬の世界市場は、先端薬の法外な価格、後期段階の探索候補薬の失敗、貧困国におけるアルツハイマー病に対する知識の低さなどにより、予測期間中に制約を受ける可能性があります。

例えば、20222年11月、ロシュグループの一員であるジェネンテック社から、アルツハイマー病による軽度認知障害（MCI）および一般に早期アルツハイマー病と呼ばれる軽度アルツハイマー病認知症の患者を対象にガンテネルマブを検討したGRADUATE IおよびII第III相試験の結果が発表されました。臨床的な低下を抑えるという研究の主目的は達成されなかっています。

COVID-19の影響分析

COVID-19分析では、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオに加え、Pricing Dynamics（パンデミック発生時および発生後の価格変動を含む、COVID以前のシナリオとの比較）、需給スペクトラム（取引制限、ロックダウン、その後の問題による需要と供給のシフト）、Government Initiatives（政府機関による市場、産業、部門の活性化の取り組み）、Maker Strategic Initiatives（メーカーの戦略的取り組み）があります。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、この地域の主要な市場プレイヤーの数が少ないことから、世界のアルツハイマー病治療薬市場に与える影響は少ないと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のアルツハイマー型認知症治療薬市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 医薬品タイプ別スニペット
  • 販売チャネル別スニペット
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 医薬品開発におけるバイオマーカーの活用と豊富なパイプライン
      • パイプラインにある薬剤の数が多い
    • 抑制要因
      • 後発医薬品の高い失敗率
    • 機会
      • 研究開発の進展とアルツハイマー病患者の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

第7章 薬剤タイプ別

  • ドネペジル
  • ガランタミン
  • リバスチグミン
  • メマンチン
  • その他

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東・アフリカ地域
    • 地域別の主なダイナミクス

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第11章 企業プロファイル

  • F. Hoffmann-La Roche
    • 会社概要
    • 医薬品の種類と概要
    • 財務概要
    • 主な発展状況
  • Novartis AG
  • Merck & Co.
  • Pfizer Inc.
  • Eli Lily and Co.
  • Biogen Inc.
  • Johnson & Johnson
  • Lupin
  • AbbVie Inc.
  • Siemens Healthineers

第12章 付録

目次
Product Code: PH662

Market Overview

The Global Alzheimer Drugs Market reached US$ 3.97 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 7.7 billion by 2030. The global alzheimer drugs market is expected to exhibit a CAGR of 8.7% during the forecast period 2023-2030.

The global market for Alzheimer's medications is expanding due to factors including the increasing prevalence of chronic diseases, including dementia, the growing size of the therapeutic pipeline, expenditures in biomarkers for diagnosis and drug development, and the creation of more sophisticated diagnostics for early detection.

The Alzheimer drugs market's drug type scope comprises Alzheimer drugs like donepezil, galantamine, rivastigmine, memantine and others, which has increased the market share for Alzheimer drugs type. These medications could lessen or regulate some behavioral and cognitive issues. Alzheimer's drugs developments and upcoming medical approvals across countries are also creating a positive outlook for market growth.

Market Dynamics

Use of Biomarkers in Drug Development and Large Pipeline Drive the Growth of the Alzheimer Drugs Market.

The risk involved in creating medication is high, and biomarkers present a practical means of reducing the risk and enhancing technical success. The understanding of Alzheimer is rapidly developing, and important biological events are now being identified. Biomarkers that can be seen by brain imaging, in the blood or in the cerebrospinal fluid (CSF) may occasionally accompany these occurrences.

By utilizing these biomarkers to improve the drug development process, it may be possible to reduce the risk associated with the creation of Alzheimer therapies. As a result, the market for Alzheimer's pharmaceuticals is being driven by the increasing significance of biomarkers in developing AD therapies.

Growing Research and Development and Rising Prevalence of Alzheimer Creates Lucrative Opportunities for Manufacturers.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for Alzheimer treatment. According to the World Alzheimer Report, there are currently 50 million people living with Alzheimer's disease or related dementia, and by 2050, that number is expected to rise to 152 million.

Additionally, the FDA has authorized the use of two pharmacological classes, cholinesterase inhibitors (Aricept, Exelon, Razadyne), and memantine (Namenda), to treat the cognitive side effects of Alzheimer's disease, such as memory loss, disorientation, and problems with thinking and reasoning. With more clinical trials being conducted for the diagnosis and treatment of Alzheimer's, the market will rise as a result.

High failure Rates of Late-Stage Drugs will Hamper the Growth of the Market

The global marketplace for Alzheimer's drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low level of knowledge of Alzheimer's disease in poor countries.

For instance, in November 20222, results from the GRADUATE I and II Phase III studies investigating gantenerumab in patients with mild cognitive impairment (MCI) owing to Alzheimer's and mild Alzheimer's dementia, generally known as early Alzheimer's disease, were released by Genentech, a member of the Roche Group. The research' main goal of decreasing clinical decline was not achieved.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global alzheimer drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global alzheimer drugs market growth over the forecast period.

Segment Analysis

The Global Alzheimer Drugs Market is segmented based on drug type, distribution channel and region.

Hospital Pharmacy from the Distribution Channel Segment Accounts for 40.1% of Market Share. Owing to Rising Hospital Admissions

The goal of hospital pharmacy is to constantly maintain and improve patient medication administration to the greatest levels imaginable. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. One of the goals is to enhance patient outcomes through the prescription, procurement, distribution, management, and review of medications.

Hospital pharmacies will see an increase in demand thanks to benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use (such as injections, suppositories, and nasal sprays), and making sure the container can be read and opened with ease. identifying potential health issues unrelated to dementia. Hence above-mentioned factors prove that hospital pharmacies will be the largest market shareholder.

Geographical Analysis

North America accounted for approximately 39.2% of the market share due to major players' strong presence and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for Alzheimer drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of Alzheimer drugs, increasing demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of Alzheimer drugs applications. Rising new product launches for using in patients with dementia or Alzheimer will drive the market growth.

Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for Alzheimer such as biomarkers, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the alzheimer drugs market include: F. Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, AbbVie, Siemens Healthineers and Lupin among others.

Why Purchase the Report?

  • To visualize the Global Alzheimer Drugs Market segmentation based on drugs type, distribution channel and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Alzheimer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Alzheimer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drugs Type
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Use of biomarkers in drug development and large pipeline
      • 4.1.1.2. Large number of drugs in pipeline
    • 4.1.2. Restraints
      • 4.1.2.1. High failure rates of late-stage drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Growing research and development and rising prevalance of Alzheimer
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Drugs Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 7.1.2. Market Attractiveness Index, By Drugs Type
  • 7.2. Donepezil *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Galantamine
  • 7.4. Rivastigmine
  • 7.5. Memantine
  • 7.6. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacy
  • 8.4. Online Pharmacy

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan

Australia

      • 9.5.5.4. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. F. Hoffmann-La Roche *
    • 11.1.1. Company Overview
    • 11.1.2. Drugs Type Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Novartis AG
  • 11.3. Merck & Co.
  • 11.4. Pfizer Inc.
  • 11.5. Eli Lily and Co.
  • 11.6. Biogen Inc.
  • 11.7. Johnson & Johnson
  • 11.8. Lupin
  • 11.9. AbbVie Inc.
  • 11.10. Siemens Healthineers

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us